Dr. Lyudmila Bazhenova, MD & Immuno-Oncology Clinical Investigator Discusses Adverse Events

Dr. Lyudmila Bazhenova, MD & Immuno-Oncology Clinical Investigator Discusses Adverse Events

Dr. Lyudmila Bazhenova, professor of Medicine and thoracic oncologist with the University of California San Diego, and active principal investigator in advanced immunotherapy-based clinical trials, highlights immunotherapy-related adverse events (AEs) for the Oncology Learning Network.

Dr. Bazhenova reports that immunotherapy is here to stay—that the breakthroughs with this class of therapy has been profound for cancer patients and specifically for this talk—non-small-cell lung cancer. She notes that immunotherapy now moves from second-line setting to first-line setting (e.g. the first treatment).

AEs & Immunotherapy

Of course, there can be any number of AEs, and Dr. Bazhenova reports that physicians should refer to resources such as the NCCN Guidelines, asthma guidelines, etc. that help explain to clinicians how to correctly manage immune-related adverse events.

What is Lacking?

According to Dr. Bazhenova, there is still a lack of knowledge—and hence uncertainty—when it comes to the use of and safety associated with use of immunotherapies on cancer patients with pre-existing autoimmune conditions, patients with HIV and hepatitis B and hepatitis C. She declares ...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee